139 related articles for article (PubMed ID: 32984784)
21. Efficacy and safety of ultra-short wave diathermy on COVID-19 pneumonia: a pioneering study.
Huang L; Li Q; Shah SZA; Nasb M; Ali I; Chen B; Xie L; Chen H
Front Med (Lausanne); 2023; 10():1149250. PubMed ID: 37342496
[TBL] [Abstract][Full Text] [Related]
22. Jin-Zhen oral liquid for pediatric coronavirus disease (COVID-19): A randomly controlled, open-label, and non-inferiority trial at multiple clinical centers.
Dong Q; Qiao H; Jiang H; Liu L; Ge Y; Zong FJ; Li Y; Dong B; Hu S; Meng D; Jin R; Wang X; Chang H; Xu X; Wang C; Cao Y; Zhang HT; Liu Q
Front Pharmacol; 2023; 14():1094089. PubMed ID: 36923353
[No Abstract] [Full Text] [Related]
23. Use of ivermectin in the treatment of Covid-19: A pilot trial.
Pott-Junior H; Paoliello MMB; Miguel AQC; da Cunha AF; de Melo Freire CC; Neves FF; da Silva de Avó LR; Roscani MG; Dos Santos SS; Chachá SGF
Toxicol Rep; 2021; 8():505-510. PubMed ID: 33723507
[TBL] [Abstract][Full Text] [Related]
24. Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial.
Zou R; Peng L; Shu D; Zhao L; Lan J; Tan G; Peng J; Yang X; Liu M; Zhang C; Yuan J; Wang H; Li S; Lu H; Zhong W; Liu Y
Front Pharmacol; 2022; 13():939573. PubMed ID: 35784723
[No Abstract] [Full Text] [Related]
25. An open-label randomized controlled trial of leflunomide in patients with acute SARS-CoV-2 omicron variant infection.
Pan Z; Wan Z; Wang Y; Zha S; Zhang J; Chen H; Hu K
Front Med (Lausanne); 2023; 10():1218102. PubMed ID: 37534317
[TBL] [Abstract][Full Text] [Related]
26. Thalidomide for the Treatment of COVID-19 Pneumonia: A Randomized Controlled Clinical Trial.
Amra B; Ashrafi F; Torki M; Hashemi M; Shirzadi M; Soltaninejad F; Sadeghi S; Salmasi M; Sami R; Darakhshandeh A; Nasirian M; Pourajam S
Adv Biomed Res; 2023; 12():14. PubMed ID: 36926422
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of Bromhexine versus Standard of Care in Reducing Viral Load in Patients with Mild-to-Moderate COVID-19 Disease Attended in Primary Care: A Randomized Open-Label Trial.
Vila Méndez ML; Antón Sanz C; Cárdenas García ADR; Bravo Malo A; Torres Martínez FJ; Martín Moros JM; Real Torrijos M; Vendrell Covisa JFJ; Guzmán Sierra O; Molina Barcena V; Viejo Pinero N; Fernández Díaz C; Arroyo Burguillo P; Blanco Gallego AM; Guirao Sánchez C; Montilla Bernabé A; Villanueva Morán MDP; Juárez Antón S; Fernández Rodríguez Á; Somoza Calvo MÁ; Cerrada EC; Pérez Mañas G; Sánchez Calso A; Vallejo Somohano F; Cauqui Díaz C; Viñas Fernández G; Molina París J; González Godoy M; Lumbreras García G; Rosado Martín J; Rodríguez Hernández A; López Antúñez S; Vázquez Perfecto G; Marcello Andrés MC; Puente García NM; Gil C; Martínez A; Soler López B
J Clin Med; 2022 Dec; 12(1):. PubMed ID: 36614943
[TBL] [Abstract][Full Text] [Related]
28. A randomised controlled trial of effectiveness and safety of Niclosamide as add on therapy to the standard of care measures in COVID-19 management.
Abdulamir AS; Gorial FI; Saadi SJ; Maulood MF; Hashim HA; Alnuaimi AS; Abdulrrazaq MK
Ann Med Surg (Lond); 2021 Sep; 69():102779. PubMed ID: 34512959
[TBL] [Abstract][Full Text] [Related]
29. Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial.
Ni L; Wen Z; Hu X; Tang W; Wang H; Zhou L; Wu L; Wang H; Xu C; Xu X; Xiao Z; Li Z; Li C; Liu Y; Duan J; Chen C; Li D; Zhang R; Li J; Yi Y; Huang W; Chen Y; Zhao J; Zuo J; Weng J; Jiang H; Wang DW
Front Med; 2021 Oct; 15(5):704-717. PubMed ID: 33909260
[TBL] [Abstract][Full Text] [Related]
30. Rationale for COVID-19 Treatment by Nebulized Interferon-β-1b-Literature Review and Personal Preliminary Experience.
Mary A; Hénaut L; Macq PY; Badoux L; Cappe A; Porée T; Eckes M; Dupont H; Brazier M
Front Pharmacol; 2020; 11():592543. PubMed ID: 33329000
[TBL] [Abstract][Full Text] [Related]
31. Interferon-α-2b aerosol inhalation is associated with improved clinical outcomes in patients with coronavirus disease-2019.
Yu J; Lu X; Tong L; Shi X; Ma J; Lv F; Wu J; Pan Q; Yang J; Cao H; Li L
Br J Clin Pharmacol; 2021 Dec; 87(12):4737-4746. PubMed ID: 33982806
[TBL] [Abstract][Full Text] [Related]
32. Effect of electroacupuncture on the repair of stress ulcer injury in neurocritical patients: A randomized clinical trial.
Li H; Li LL; Wang J; Wang YQ; Wang L; Yuan L; Chen WT; Song JG
Front Med (Lausanne); 2022; 9():1001584. PubMed ID: 36465896
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of BREATHOX
Tanni S; Wehrmeister F; Prudente R; Damatto F; Breda Neto C; Oliveira L; Pagan L; Gatto M; Vieira L; Coelho L; Rezende D; Machado L; Mota G; Gaiato M; Santaella F; Campos E; Franco E; Callegari M; Okoshi MP; Weinreich U
J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37763015
[TBL] [Abstract][Full Text] [Related]
34. An open clinical evaluation of selected siddha regimen in expediting the management of COVID-19 -a randomized controlled study.
Chitra SM; Mallika P; Anbu N; Narayanababu R; Sugunabai A; David Paul Raj RS; Premnath D
J Ayurveda Integr Med; 2022; 13(1):100397. PubMed ID: 33519133
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of a standardized herbal formulation from
Soleiman-Meigooni S; Hoseini Yekta N; Sheikhan HR; Aminianfar M; Hamidi-Farahani R; Ahmadi M; Asgari A; Kazemi-Galougahi MH; Rahimi R
J Ayurveda Integr Med; 2022; 13(4):100670. PubMed ID: 36320214
[TBL] [Abstract][Full Text] [Related]
36. Inhalation phage therapy as a new approach to preventing secondary bacterial pneumonia in patients with moderate to severe COVID-19: A double-blind clinical trial study.
Samaee HR; Eslami G; Rahimzadeh G; Saeedi M; Davoudi Badabi A; Asare-Addo K; Nokhodchi A; Roozbeh F; Moosazadeh M; Ghasemian R; Alikhani A; Rezai MS
J Drug Deliv Sci Technol; 2023 Jun; 84():104486. PubMed ID: 37123173
[TBL] [Abstract][Full Text] [Related]
37. A triple combination of treatments on moderate COVID-19.
Bao C; Li B; Zhou Y
Open Med (Wars); 2021; 16(1):769-772. PubMed ID: 34027106
[TBL] [Abstract][Full Text] [Related]
38. Oral Liushen pill for patients with COVID-19: A prospective randomized controlled trial.
Zhang J; Liu Y; Lei W; Shen J; Lu J; Tao T; Cao X; Yang Z; Huang J; Shi C
Pulm Circ; 2023 Jan; 13(1):e12187. PubMed ID: 36733313
[TBL] [Abstract][Full Text] [Related]
39. Role of Dantabija, Haridra, and Zingiber (DHZ) combination to restore health and immunity in mild to moderate COVID-19 patients.
Kumar Y; Agarwal M; Bhushan D; Pati BK; Jha K; Kumari A
J Family Med Prim Care; 2022 Oct; 11(10):6067-6073. PubMed ID: 36618209
[TBL] [Abstract][Full Text] [Related]
40. Celebrex Adjuvant Therapy on Coronavirus Disease 2019: An Experimental Study.
Hong W; Chen Y; You K; Tan S; Wu F; Tao J; Chen X; Zhang J; Xiong Y; Yuan F; Yang Z; Chen T; Chen X; Peng P; Tai Q; Wang J; Zhang F; Li YX
Front Pharmacol; 2020; 11():561674. PubMed ID: 33312125
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
